Berlin Heart EXCOR® Adult BVAD
Latest Clinical Results

Our patients.
Our mission!

Durable circulatory support with a paracorporeal device as an option for pediatric and adult heart failure patients*:

Patient characteristics (n=29):
Median age: (23 – 48y)
Preoperative ST-MC: 73%
INTERMACS level 1: 62%

The overall survival at one year is 86%

Patients with biventricular failure displayed a high survival on device to HTx and a good long-term survival probability.

„Despite severe illness, patient survival on EXCOR was high, and the long-term overall survival probability following heart transplantation and recovery was advantageous.“

Read more about: https://www.jtcvs.org/article/S0022-5223(20)31166-1/fulltext

*Bartfay et al “Durable circulatory support with a paracorporeal device as an option for pediatric and adult heart failure patients” J Thorac Cardiovasc Surgery 2020
Successful support of biventricular heart failure patients by new EXCOR® Adult pumps with bileaflet valves: a prospective study*

Patient characteristics (n=12):
Median age: 45 years (21-58y)
Preoperative ECMO/ IABP: 67%
INTERMACS level 1-2: 92%

Survival at 18 months:

Beyond the initial follow up period of 12 months, all patients who were still alive on BVAD support were then transplanted successfully with a median time on support of 668 days (range 373-926). In total 92% of patients where successfully bridged to HTx using long-term pulsatile BVAD support.

“EXCOR® Adult blood pumps with bi-leaflet valves show an outstanding survival of 92% in patients with biventricular heart failure.”

Matthias was able to train with his bike on the Excor mobile. After two years on the system, he is now successfully transplanted.

Jenny integrated the Excor mobile into her everyday life and was successfully transplanted after almost six months of support.
The access to some or all shown products may be restricted by country-specific regulatory approvals. The use of EXCOR® VAD for adults, RVAD-support, EXCOR® venous cannulas with grafts, Excor mobile and EXCOR® Active is not FDA-approved and not available for commercial use in the US.